



Sword & Shield Pharma Ltd.

CIN: L24231GJ1995PLC024809

Security Code: 531637 Security ID: SWORDNSH

13th February, 2019

To,
The Listing Compliance Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Ref: Reg. 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Subject: Outcome of the Board Meeting held today and submission of Unaudited Financial results for the quarter ended 31st December, 2018

Dear Sir/ Madam,

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Wednesday, 13th February, 2019 commenced at 09.00 am (GMT-4)/ 6.30 PM (IST) and concluded at 09.30 am (GMT-4)/7.00 PM (IST) has Considered, approved and took on record the unaudited financial results for the quarter and nine months ended on 31st December, 2018 along with Limited Review Report.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For, **SWORD AND SHIELD PHARMA LTD**

Pooja Kadam

POOJA KADAM
Company Secretary & Compliance Officer
(ACS: 43019)





B. K. PATEL & CO
Chartered Accountants

401, VRAJ Valencia, Behind Mahindra Show Room, Near Sola Overbridge,
S.G.Highway, Sola, AHMEDABAD - 380 060. Gujarat
PHONES : 079 - 2970 0973
Email : bkpatelandco@gmail.com

Limited Review Report

To,
The Board of Directors,
Sword & Shield Pharma Limited.
Ahmedabad

We have reviewed the accompanying statement of Un-Audited Financial Results (the statements) together with the relevant notes thereon of **Sword & Shield Pharma Limited**, Ahmedabad for the quarter and nine months ended on **December 31, 2018** prepared by the Company in pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a review report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by independent auditor of entity' issued by The Institute of Chartered Accountants of India which requires that we plan and perform the review to obtain moderate assurance as to whether the financial information's are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is subsequently less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified during the course an Audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with Indian accounting standards as specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, or that it contains any material misstatement.

For, B. K. PATEL & CO
Chartered Accountants
Firm Regn No. 112647W



13-2-2019
Ahmedabad


K. D. Patel
Partner
Membership No.39919

SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809

Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi,
Ahmedabad - 380 006

Website: www.swordnshieldpharma.com

Contact: +91 98250 79759

Un-Audited Financial Results for the Quarter Ended December 31, 2018

Financial Results - Ind-AS

(Amount in LAKHS)

Particulars		3 months ended (dd- mm-yyyy)	3 months ended (dd- mm-yyyy)	3 months ended (dd- mm-yyyy)	9 months ended (dd- mm-yyyy)	9 months ended (dd- mm-yyyy)	Previous Financial Year ended
A	Date of start of reporting period	1-Oct-18	1-Jul-18	1-Oct-17	1-Apr-18	1-Apr-17	1-Apr-17
B	Date of end of reporting period	31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
Part I							
1	Income						
	Revenue from operations	0.702	0.477	0.518	1.179	2.895	2.895
	Other income	0.006	0.003	0.021	0.010	0.035	0.058
	Total income	0.708	0.480	0.539	1.189	2.929	2.952
2	Expenses						
(a)	Cost of materials consumed	0.000	0.000	0.000	0.000	0.000	0.000
(b)	Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(d)	Employee benefit expense	0.872	0.939	1.212	2.540	3.279	4.539
(e)	Finance costs	0.000	0.000	0.000	0.000	0.006	0.046
(f)	Depreciation, depletion and amortisation expense	0.000	0.000	0.000	0.000	0.000	0.000
(f)	Other Expenses						
1	Other Expenses	0.775	0.968	2.775	5.426	11.618	14.033
	Total other expenses	0.775	0.968	2.775	5.426	11.618	14.033
	Total expenses	1.647	1.907	3.987	7.967	14.904	18.619
3	Total profit before exceptional items and tax	-0.939	-1.427	-3.449	-6.778	-11.974	-15.666
4	Exceptional Items & Prior Period Exps	0.000	0.000	0.000	0.000	0.000	0.400

5	Total profit before tax	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
7	Tax expense						
8	Current tax	0.000	0.000	0.000	0.000	0.000	0.000
9	Deferred tax	0.000	0.000	0.000	0.000	0.000	0.000
10	Total tax expenses	0.000	0.000	0.000	0.000	0.000	0.000
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000	0.000	0.000
14	Net Profit Loss for the period from continuing operations	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
15	Profit (loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
16	Tax expense of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
17	Net profit (loss) from discontinued operation after tax	0.000	0.000	0.000	0.000	0.000	0.000
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000
21	Total profit (loss) for period	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
22	Other comprehensive income net of taxes	0.000	0.000	0.000	0.000	0.000	0.000
23	Total Comprehensive Income for the period	0.000	0.000	0.000	0.000	0.000	0.000
24	Total profit or loss, attributable to						
	Profit or loss, attributable to owners of parent						
	Total profit or loss, attributable to non-controlling interests						
25	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
26	Details of equity share capital						
	Paid-up equity share capital	51506000.00	51506000.00	51506000.00	51506000.00	51506000.00	49877060.00
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
27	Details of debt securities						
	Paid-up debt capital						
	Face value of debt securities						
28	Reserves excluding revaluation reserve						-495.94
29	Debenture redemption reserve						
30	Earnings per share						
	Earnings per equity share for continuing operations						
	Basic earnings (loss) per share from continuing operations	0.000	0.000	0.000	0.000	0.000	0.000
	Diluted earnings (loss) per share from continuing operations	-0.018	-0.028	-0.067	-0.132	-0.232	-0.322
	Earnings per equity share for discontinued operations						

